Brief: AstraZeneca Says Enhertu Demonstrates 14.3 Month Median Progression-Free Survival In Destiny-Lung04 Phase III Trial
14/09/2026 03:33
BRIEF-AstraZeneca Says Enhertu Demonstrates 14.3 Month Median Progression-Free Survival In Destiny-Lung04 Phase III Trial Sept 13 (Reuters) - AstraZeneca PLC AZN.L:
ASTRAZENECA - ENHERTU DEMONSTRATES 14.3 MONTH MEDIAN PROGRESSION-FREE SURVIVAL IN DESTINY-LUNG04 PHASE III TRIAL
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines